84 / 86
Preplanned OS Subgroups Analysis
Overall
176/228 181/224
0.768 (0.618-0.954)
13.5
11.5
Age group (years)
<65
≥65
138/178
38/50
148/178
33/46
0.728 (0.569-0.931)
0.766 (0.445-1.319)
13.5
13.5
11.3
13.2
Sex
Female
Male
124/161
52/67
110/142
71/82
0.896 (0.682-1.175)
0.591 (0.402-0.868)
13.2
14.7
12.3
9.6
Prior regimens for advanced STS
2
>2
92/121
84/107
92/122
89/102
0.902 (0.671-1.214)
0.640 (0.466-0.879)
13.9
13.2
12.3
10.1
Stratification region*
Region 1
Region 2
Region 3
63/87
85/106
28/35
69/86
84/105
28/33
0.669 (0.466-0.958)
0.890 (0.653-1.214)
0.667 (0.380-1.171)
15.3
13.3
11.4
11.5
11.5
9.7
Group/Subgroup
Eribulin Dacarbazine
— EVENTS/n —
Eribulin Dacarbazine
MEDIAN (mos)
HR (95% CI)
0.25
1
4
16
Favors Eribulin
Favors Dacarbazine
1. Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502
2. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37
*Region 1: USA, Canada; Region 2: Western Europe, Australasia, Israel; Region 3: Eastern Europe, Latin America, Asia.